Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Aardvark Therapeutics Inc (AARD)

Aardvark Therapeutics Inc (AARD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD PR Newswire - Thu May 28, 9:00AM CDT

NEW YORK , May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD).  Such investors...

AARD : 3.68 (-6.60%)
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS PR Newswire - Thu May 28, 8:00AM CDT

SAN FRANCISCO , May 28, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics ( NASDAQ: AARD ) saw the price of their shares crater $7.02 (-56%) after the company announced...

AARD : 3.68 (-6.60%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD PR Newswire - Thu May 21, 5:40PM CDT

NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD). Such investors are...

AARD : 3.68 (-6.60%)
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS PR Newswire - Thu May 21, 8:00AM CDT

SAN FRANCISCO , May 21, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics ( NASDAQ: AARD ) saw the price of their shares crater $7.02 (-56%) after the company announced...

AARD : 3.68 (-6.60%)
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman PR Newswire - Tue May 19, 11:30AM CDT

SAN FRANCISCO , May 19, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics ( NASDAQ: AARD ) saw the price of their shares crater $7.02 (-56%) after the company announced...

AARD : 3.68 (-6.60%)
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold GlobeNewswire - Thu May 14, 3:01PM CDT

SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule...

AARD : 3.68 (-6.60%)
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman PR Newswire - Thu May 7, 12:30PM CDT

SAN FRANCISCO , May 7, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics ( NASDAQ: AARD ) saw the price of their shares crater $7.02 (-56%) after the company announced...

AARD : 3.68 (-6.60%)
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire - Thu May 7, 7:00AM CDT

ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations...

AARD : 3.68 (-6.60%)
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman PR Newswire - Wed Apr 22, 1:25PM CDT

SAN FRANCISCO , April 22, 2026 /PRNewswire/ - On March 2, 2026, investors in Aardvark Therapeutics ( NASDAQ: AARD ) saw the price of their shares crater $7.02 (-56%) after the company announced...

AARD : 3.68 (-6.60%)
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman PR Newswire - Fri Apr 10, 3:17PM CDT

SAN FRANCISCO , April 10, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics ( NASDAQ: AARD ) saw the price of their shares crater $7.02 (-56%) after the company announced...

AARD : 3.68 (-6.60%)

Barchart Exclusives

Netflix Rolls Out Generative AI Tools to Fix the Content Overload Problem It Created Barchart - Sun Jun 7, 2:00PM CDT
Netflix is rolling out generative AI tools like voice search and mood-based picks to help subscribers beat content overload and find shows faster. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.